August 5, 2011 — Elekta has signed a definitive agreement to acquire Nucletron, a worldwide provider of technology for brachytherapy treatment planning and delivery.
Nucletron will add 1,000 new customers to Elekta’s customer base of more than 5,000. The two companies have synergistic product and technology portfolios. The combination will lead to enhanced solutions for customers and patients, and will allow the enlarged group to take mutual advantage of Nucletron’s expertise in brachytherapy combined with Elekta’s global presence, particularly in emerging markets.
Under the terms of the agreement, Elekta will pay cash consideration of EUR 365 million to acquire Nucletron on a cash and debt-free basis. The transaction, which has been approved by the Board of Directors of both companies, is subject to regulatory approval and is expected to close in early autumn 2011.
The acquisition is expected to be accretive to Elekta’s cash earnings within twelve months. The transaction will be financed through existing cash on hand and available credit facilities. The proforma business will continue to have a strong financial profile.
For more information: www.elekta.com or www.nucletron.com
May 17, 2024 
